AADIAadi Bioscience, Inc.

Nasdaq aadibio.com


$ 1.84 $ -0.04 (-2.13 %)    

Wednesday, 15-May-2024 15:59:51 EDT
QQQ $ 452.83 $ 3.91 (0.87 %)
DIA $ 399.31 $ 3.73 (0.94 %)
SPY $ 529.09 $ 3.17 (0.6 %)
TLT $ 92.14 $ 1.28 (1.41 %)
GLD $ 220.89 $ 2.79 (1.28 %)
$ 1.88
$ 1.90
$ 0.00 x 0
$ 0.00 x 0
$ 1.83 - $ 1.92
$ 1.55 - $ 8.60
182,899
na
50.72M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-13-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-11-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-07-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 03-15-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 03-07-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 05-16-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
35 11-13-2015 09-30-2015 10-Q
36 08-13-2015 06-30-2015 10-Q
37 05-13-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-14-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-aadi-bioscience

HC Wainwright & Co. analyst Robert Burns reiterates Aadi Bioscience (NASDAQ:AADI) with a Neutral.

 aadi-bioscience-q1-2024-gaap-eps-068-misses-065-estimate-sales-5353m-miss-6454m-estimate

Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0...

 reported-sunday-aadi-bioscience-presented-new-subgroup-analysis-of-patients-with-advanced-malignant-pecoma-of-gynecologic-origin-treated-with-nab-sirolimus-at-society-of-gynecologic-oncology

Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gyneco...

 aadi-bioscience-q4-gaap-eps-060-beats-065-estimate-sales-633m-beat-629m-estimate

Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.6...

 earnings-scheduled-for-march-13-2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

 aadi-bioscience-earnings-preview
Aadi Bioscience Earnings Preview
03/12/2024 17:01:21

 why-bitdeer-technologies-shares-are-trading-higher-by-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...

 why-biovie-shares-are-trading-lower-by-around-42-here-are-20-stocks-moving-premarket

Shares of BioVie Inc. (NASDAQ: BIVI) fell sharply in today’s pre-market trading after the company reported pricing of public ...

 aadi-bioscience-announces-publication-of-long-term-efficacy-and-safety-data-further-supporting-fyarro-for-the-treatment-of-malignant-pecoma

After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients ...

 aadi-bioscience-announces-poster-presentations-at-the-2024-american-society-of-clinical-oncology-genitourinary-cancers-symposium

Real-world genomic analysis highlights unmet medical need in GU cancer patients with TSC1/2 inactivating alterations

 top-3-health-care-stocks-that-are-preparing-to-pump-this-month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 cancer-player-aadi-bioscience-downgraded-analyst-highlights-worse-than-expected-response-rates

Friday, Aadi Bioscience Inc (NASDAQ: AADI) released results from a planned interim analysis on the first third of participants ...

 why-quanex-building-products-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth...

 dow-edges-higher-darden-restaurants-earnings-top-views

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 70 points on Friday. The Dow traded...

 piper-sandler-maintains-overweight-on-aadi-bioscience-lowers-price-target-to-5

Piper Sandler analyst Joseph Catanzaro maintains Aadi Bioscience (NASDAQ:AADI) with a Overweight and lowers the price target...

 us-stocks-mixed-costco-posts-upbeat-earnings

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 75 points on Friday. The Dow traded down 0.20% ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION